| 1. |
|
|
| 2. |
- Glasbey, JC, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 3. |
|
|
| 4. |
- Pearson, A. D. J., et al.
(författare)
-
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
- 2020
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049. ; 136, s. 116-129
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major need to accelerate the evaluation of innovative medicines, yet drug development continues to be adult-focused. Furthermore, the large number of competing agents in rare patient populations requires coordinated prioritisation, within the global regulatory framework and cooperative group initiatives. Methods: The fourth multi-stakeholder Paediatric Strategy Forum focused on AML in children and adolescents. Results: CD123 is a high priority target and the paediatric development should be accelerated as a proof-of-concept. Efforts must be coordinated, however, as there are a limited number of studies that can be delivered. Studies of FLT3 inhibitors in agreed paediatric investigation plans present challenges to be completed because they require enrolment of a larger number of patients than actually exist. A consensus was developed by industry and academia of optimised clinical trials. For AML with rare mutations that are more frequent in adolescents than in children, adult trials should enrol adolescents and when scientifically justified, efficacy data could be extrapolated. Methodologies and definitions of minimal residual disease need to be standardised internationally and validated as a new response criterion. Industry supported, academic sponsored platform trials could identify products to be further developed. The Leukaemia and Lymphoma Society PedAL/EUpAL initiative has the potential to be a major advance in the field. Conclusion: These initiatives continue to accelerate drug development for children with AML and ultimately improve clinical outcomes. (C) 2020 Elsevier Ltd. All rights reserved.
|
|
| 5. |
|
|
| 6. |
- Wingbrant, Helena, et al.
(författare)
-
Co-sputtered metal and SiO2 layers for use in thick-film MISiC NH3 sensors
- 2006
-
Ingår i: IEEE Sensors Journal. - 1530-437X. ; 6:4, s. 887-897
-
Tidskriftsartikel (refereegranskat)abstract
- High-temperature metal-insulator-silicon-carbide (MISiC) sensors are currently under development for use as NH3 sensors in selective-catalytic-reduction (SCR) systems in diesel engines or non-SCR (NSCR) systems in boilers. The detection of NH3 by these sensors requires the presence of triple points where the gas, the metal, and the insulator meet. These triple points have traditionally been located at the interface between the insulator and a porous metal. However, to facilitate the long-term stability of the devices when used in a harsh environment, a nonporous gate material would be preferred. Here, the behavior of the samples where such triple points have been introduced in a dense film through cosputtering of the insulator (SiO 2), and either Pt or Ir is studied. The NH3 sensitivity of the materials was found to be in accordance with the earlier investigations on Si-based samples with cosputtered gate materials. Several metal-to-insulator ratios for each of the metals Pt and Ir were studied. The sensitivity of the layers as well as their selectivity to different concentrations of NH3 at temperatures ranging from 150 degC to 450 degC was investigated. The films containing 60%-70% Pt or Ir were found to give a high sensitivity toward NH3. These samples were shown to be sensitive also to propylene and H2 but were rather insensitive to NO and CO.
|
|
